U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year.
with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger. A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
FDA approves new drug to protect babies from RSVThe FDA approved a new drug to protect babies from RSV, the leading cause of hospitalization for U.S. infants.
Les mer »
New drug to protect babies and toddlers from RSV gets FDA approval ahead of cold seasonLast year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
Les mer »
New drug to protect babies and toddlers from RSV gets FDA approval ahead of cold seasonLast year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
Les mer »
FDA approves antibody to protect infants from RSV | CNNParents and pediatricians will have a new option this fall to protect babies from a lung-attacking virus that is the leading cause of hospitalization in infants under a year of age in the United States every year.
Les mer »
FDA approves antibody shot to protect infants from potentially deadly virus RSVThis injection was approved to protect against the annual leading cause of hospitalization in infants under a year old in the U.S.
Les mer »
FDA approves antibody shot to protect infants from potentially deadly virus RSVThis injection was approved to protect against the annual leading cause of hospitalization in infants under a year old in the U.S.
Les mer »